BioShin
company
About
BioShin is a clinical stage biopharmaceutical company.
- Shanghai,Shanghai,China
- 1 - 10
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $60M
- Industries
- Biotechnology,Health Care,Life Science,Pharmaceutical
- Founded date
- Jan 1, 2013
- Number Of Employee
- 1 - 10
- Operating Status
- Active
- Legal Name
- BioShin Ltd.
BioShin is a wholly owned subsidiary of Biohaven Pharmaceuticals, a public biotech company. BioShin is a clinical stage biopharmaceutical company focused on developing medicines. It has proven leadership from global industry and academic settings and a portfolio of innovative, late stage product candidates targeting neurological and neuropsychiatric diseases, including rare disorders.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$60M
BioShin has raised a total of
$60M
in funding over 2 rounds. Their latest funding was raised on
Sep 28, 2020 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 28, 2020 | Series A | $60M | 5 |
OrbiMed
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
5
BioShin is funded by 5 investors.
OrbiMed
and Cormorant Asset Management
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
OrbiMed
|
Yes | Series A |
Cormorant Asset Management
|
— | Series A |
HBM Healthcare Investments AG
|
— | Series A |
Surveyor Capital
|
— | Series A |
Suvretta Capital Management
|
— | Series A |
Employee Profiles
Number of Employee Profiles
4
BioShin has 4 current employee profiles, including
Board member David Wang
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
